An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen

Carlo Zibera, Paolo Pedrazzoli, Luisa Ponchio, Nadia Gibelli, Annalisa Lanza, Gian Antonio Da Prada, Alberto Zambelli, Cesare Perotti, Lorella Torretta, Laura Salvaneschi, Gioacchino Robustelli Della Cuna

Research output: Contribution to journalArticle

Abstract

Background and Objectives. Based on our preliminary experience, we have further evaluated the capacity of the paclitaxel/epirubicin combination (at the dose of 175 and 90 mg/m2, respectively) plus G-CSF to mobilize hematopoietic progenitors into the circulation. Design and Methods. The study was conducted in a homogeneous cohort of 25 stage IV breast cancer patients showing response to three cycles of the same chemotherapy regimen and who were included in a high-dose chemotherapy program. Results. In most cases (68%) more than 5 x 106 CD34+ cells/kg b.w. (the threshold fixed in our study) were collected by a single leukapheresis, 28% and 4% of patients requiring 2 and 3 procedures, respectively. Based on the CD34+ cell count in the peripheral blood, most of the leukaphereses (53%) were performed on day 11 after chemotherapy. More than 50 CD34+ cells/mL along with a preleukapheresis WBC count between 10 and 20 x 109/L predicted that only a single harvest would be required in 100% of cases. The evaluation of the clonogenic potential of collected cells showed that a large number of committed colony-forming cells (CFCs) and more primitive long-term culture- initiating cell (LTC-IC) hematopoietic progenitors were present in 20 harvests studied. Interpretations and Conclusions. These data demonstrate that the epirubicin/paclitaxel combination followed by G-CSF, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor cells into the circulation which can then be safely employed to support myeloablative regimens.

Original languageEnglish
Pages (from-to)924-929
Number of pages6
JournalHaematologica
Volume84
Issue number10
Publication statusPublished - Oct 1999

Fingerprint

Epirubicin
Hematopoietic Stem Cells
Paclitaxel
Breast Neoplasms
Leukapheresis
Drug Therapy
Granulocyte Colony-Stimulating Factor
Stem Cells
Cell Count

Keywords

  • Apheresis
  • Epirubicin
  • High dose chemotherapy
  • Paclitaxel
  • Peripheral blood progenitors

ASJC Scopus subject areas

  • Hematology

Cite this

An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen. / Zibera, Carlo; Pedrazzoli, Paolo; Ponchio, Luisa; Gibelli, Nadia; Lanza, Annalisa; Da Prada, Gian Antonio; Zambelli, Alberto; Perotti, Cesare; Torretta, Lorella; Salvaneschi, Laura; Della Cuna, Gioacchino Robustelli.

In: Haematologica, Vol. 84, No. 10, 10.1999, p. 924-929.

Research output: Contribution to journalArticle

Zibera, Carlo ; Pedrazzoli, Paolo ; Ponchio, Luisa ; Gibelli, Nadia ; Lanza, Annalisa ; Da Prada, Gian Antonio ; Zambelli, Alberto ; Perotti, Cesare ; Torretta, Lorella ; Salvaneschi, Laura ; Della Cuna, Gioacchino Robustelli. / An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen. In: Haematologica. 1999 ; Vol. 84, No. 10. pp. 924-929.
@article{3b1a221049e246c2993126aa4c06e8ce,
title = "An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen",
abstract = "Background and Objectives. Based on our preliminary experience, we have further evaluated the capacity of the paclitaxel/epirubicin combination (at the dose of 175 and 90 mg/m2, respectively) plus G-CSF to mobilize hematopoietic progenitors into the circulation. Design and Methods. The study was conducted in a homogeneous cohort of 25 stage IV breast cancer patients showing response to three cycles of the same chemotherapy regimen and who were included in a high-dose chemotherapy program. Results. In most cases (68{\%}) more than 5 x 106 CD34+ cells/kg b.w. (the threshold fixed in our study) were collected by a single leukapheresis, 28{\%} and 4{\%} of patients requiring 2 and 3 procedures, respectively. Based on the CD34+ cell count in the peripheral blood, most of the leukaphereses (53{\%}) were performed on day 11 after chemotherapy. More than 50 CD34+ cells/mL along with a preleukapheresis WBC count between 10 and 20 x 109/L predicted that only a single harvest would be required in 100{\%} of cases. The evaluation of the clonogenic potential of collected cells showed that a large number of committed colony-forming cells (CFCs) and more primitive long-term culture- initiating cell (LTC-IC) hematopoietic progenitors were present in 20 harvests studied. Interpretations and Conclusions. These data demonstrate that the epirubicin/paclitaxel combination followed by G-CSF, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor cells into the circulation which can then be safely employed to support myeloablative regimens.",
keywords = "Apheresis, Epirubicin, High dose chemotherapy, Paclitaxel, Peripheral blood progenitors",
author = "Carlo Zibera and Paolo Pedrazzoli and Luisa Ponchio and Nadia Gibelli and Annalisa Lanza and {Da Prada}, {Gian Antonio} and Alberto Zambelli and Cesare Perotti and Lorella Torretta and Laura Salvaneschi and {Della Cuna}, {Gioacchino Robustelli}",
year = "1999",
month = "10",
language = "English",
volume = "84",
pages = "924--929",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen

AU - Zibera, Carlo

AU - Pedrazzoli, Paolo

AU - Ponchio, Luisa

AU - Gibelli, Nadia

AU - Lanza, Annalisa

AU - Da Prada, Gian Antonio

AU - Zambelli, Alberto

AU - Perotti, Cesare

AU - Torretta, Lorella

AU - Salvaneschi, Laura

AU - Della Cuna, Gioacchino Robustelli

PY - 1999/10

Y1 - 1999/10

N2 - Background and Objectives. Based on our preliminary experience, we have further evaluated the capacity of the paclitaxel/epirubicin combination (at the dose of 175 and 90 mg/m2, respectively) plus G-CSF to mobilize hematopoietic progenitors into the circulation. Design and Methods. The study was conducted in a homogeneous cohort of 25 stage IV breast cancer patients showing response to three cycles of the same chemotherapy regimen and who were included in a high-dose chemotherapy program. Results. In most cases (68%) more than 5 x 106 CD34+ cells/kg b.w. (the threshold fixed in our study) were collected by a single leukapheresis, 28% and 4% of patients requiring 2 and 3 procedures, respectively. Based on the CD34+ cell count in the peripheral blood, most of the leukaphereses (53%) were performed on day 11 after chemotherapy. More than 50 CD34+ cells/mL along with a preleukapheresis WBC count between 10 and 20 x 109/L predicted that only a single harvest would be required in 100% of cases. The evaluation of the clonogenic potential of collected cells showed that a large number of committed colony-forming cells (CFCs) and more primitive long-term culture- initiating cell (LTC-IC) hematopoietic progenitors were present in 20 harvests studied. Interpretations and Conclusions. These data demonstrate that the epirubicin/paclitaxel combination followed by G-CSF, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor cells into the circulation which can then be safely employed to support myeloablative regimens.

AB - Background and Objectives. Based on our preliminary experience, we have further evaluated the capacity of the paclitaxel/epirubicin combination (at the dose of 175 and 90 mg/m2, respectively) plus G-CSF to mobilize hematopoietic progenitors into the circulation. Design and Methods. The study was conducted in a homogeneous cohort of 25 stage IV breast cancer patients showing response to three cycles of the same chemotherapy regimen and who were included in a high-dose chemotherapy program. Results. In most cases (68%) more than 5 x 106 CD34+ cells/kg b.w. (the threshold fixed in our study) were collected by a single leukapheresis, 28% and 4% of patients requiring 2 and 3 procedures, respectively. Based on the CD34+ cell count in the peripheral blood, most of the leukaphereses (53%) were performed on day 11 after chemotherapy. More than 50 CD34+ cells/mL along with a preleukapheresis WBC count between 10 and 20 x 109/L predicted that only a single harvest would be required in 100% of cases. The evaluation of the clonogenic potential of collected cells showed that a large number of committed colony-forming cells (CFCs) and more primitive long-term culture- initiating cell (LTC-IC) hematopoietic progenitors were present in 20 harvests studied. Interpretations and Conclusions. These data demonstrate that the epirubicin/paclitaxel combination followed by G-CSF, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor cells into the circulation which can then be safely employed to support myeloablative regimens.

KW - Apheresis

KW - Epirubicin

KW - High dose chemotherapy

KW - Paclitaxel

KW - Peripheral blood progenitors

UR - http://www.scopus.com/inward/record.url?scp=0033205035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033205035&partnerID=8YFLogxK

M3 - Article

C2 - 10509041

AN - SCOPUS:0033205035

VL - 84

SP - 924

EP - 929

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -